|
|||||
|
|
| 雷珠单抗治疗湿性AMD的研究进展 | |
| 引用本文： | 孔丽,王文娟,贺荣华,周国宏. 雷珠单抗治疗湿性AMD的研究进展[J]. 国际眼科纵览, 2016, 0(6): 400-404. DOI: 10.3760/cma.j.issn.1673-5803.2016.06.009 |
| 作者姓名： | 孔丽 王文娟 贺荣华 周国宏 |
| 作者单位： | 1. 山西医科大学解剖教研室, 太原,030001;2. 山西省眼科医院泪道病科, 太原,030002;3. 山西医科大学第一临床医学院, 太原,030001 |
| 基金项目： | The Key Science and Technology Program of the Health Department of Shanxi Province(2011057)，Natural Science Foundation of Shanxi (2014011043-7)山西省卫生厅科技攻关计划项目(2011057):山西省自然科学基金项目(2014011043-7) |
| 摘 要： | 湿性年龄相关性黄斑变性(age-related macular degeneration,AMD)是老年人群视力丧失的主要原因之一,目前其发病原因尚不明确.研究已证实血管内皮生长因子与湿性AMD有明确相关性,已有多种抗血管内皮生长因子的药物应用于其治疗.玻璃体腔注射雷珠单抗能抑制血管内皮生长因子,阻断新生血管生长及渗漏而发挥治疗作用,其在湿性AMD的治疗中已显示出确切疗效.本文对雷珠单抗治疗湿性AMD的进展作一综述,包括雷珠单抗治疗湿性AMD的方案及疗效,影响其疗效的因素,联合治疗,以及雷珠单抗治疗湿性AMD的不良反应等几个方面. |
| 关 键 词： | 雷珠单抗 湿性年龄相关性黄斑变性 血管内皮生长因子 |
Progress in the treatment of wet age-related macular degeneration with Ranibizumab |
|
| Abstract: | Wet age-related macular degeneration (AMD) is one of the main causes of vision loss in elderly people,and its etiology is not clear.In terms of pathogenesis,it has been confirmed that vascular endothelial growth factor and wet AMD have a clear correlation.Therefore,there are many kinds of anti-vascular endothelial growth factor drugs used in the disease.Intravitreal Ranibizumab can inhibit vascular endothelial growth factor and block the growth and leakage of new blood vessels to play a role.The Ranibizumab has been shown to be a definite therapeutic effect in the treatment of wet AMD.The progress of Ranibizumab in the treatment of wet AMD is reviewed in this article,including the treatment efficacy,the factors of affecting the efficacy,the combined therapy,and the adverse reaction and so on. |
| Keywords: | ranibizumab wet age-related macular degeneration vascular endothelial growth factor |
| 本文献已被 万方数据 等数据库收录！ | |